USE OF FAS LIGAND TO SUPPRESS ARTHRITIS

描述：几个小组的初步报告表明， 基于Fas配体的治疗预防移植排斥反应的可能性 治疗自身免疫性疾病，诱导免疫耐受，治疗 癌症。利用Fas配体抑制T淋巴细胞介导的免疫 回复“受美国专利号5,759,536、Donald Bellgrau和 理查德·C·杜克，发明家。Ceres制药公司已获得这项技术的许可 来自科罗拉多大学。这一阶段SBIR的总体目标是 应用是在一个成熟的小鼠模型上开发和测试 关节炎，商用重组腺病毒基因治疗载体 编码突变版本的Fas配体，具有增强的治疗潜力。 这些载体及其产生和应用于治疗的策略 人类类风湿性关节炎(美国正在申请专利)将获得许可 用于提交调查文件的制药和/或生物技术公司 新药(IND)在FDA的申请，以期进入I期临床 在人类身上的踪迹。 建议的商业应用：不可用

DESCRIPTION: Preliminary reports by several groups have demonstrated the potential for Fas ligand-based therapy to prevent transplant rejection, to treat autoimmune disease, to induce immunological tolerance and to treat cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune Responses" is protected by U.S. Patent No. 5,759,536, Donald Bellgrau and Richard C. Duke, Inventors. CERES Pharmaceuticals has licensed this Technology from the University of Colorado. The overall goal of this Phase I SBIR application is to develop and test in a well-established mouse model of arthritis, commercially-useful recombinant adenoviral gene therapy vectors encoding mutated versions of Fas ligand with enhanced therapeutic potential. These vectors and strategies for their production and application to treat human rheumatoid arthritis (U.S. Patents Pending) will be licensed to Pharmaceutical and/or Biotechnology companies for use in filing Investigational New Drug (IND) Applications with the FDA in anticipation of phase I clinical trails in humans. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE